CMMB
Chemomab Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.09
−0.91%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +37.3%
- EBIT
- +37.2%
- EPS
- +57.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +96.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- +35.3%
- EBIT
- +35.1%
- Net income
- +35.5%
- EPS
- +97.9%
- Free cash flow
- +27.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026